報價延遲最少15分鐘:2026/04/24 02:13 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
31 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.32/-2.91
|
|
企業價值
1.37B
|
| 資產負債 |
|
每股賬面淨值
6.95
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors. |
